Page 1 | Search Results | Blood Advances | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

Andrew Jay Portuguese, Cassandra Sunga, Rebecca Kruse-Jarres, Terry Gernsheimer, Janis Abkowitz

Blood Adv (2021) 5 (13): 2794–2798.

https://doi.org/10.1182/bloodadvances.2021004957

Published: 2021

Journal Articles

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Shruti Chaturvedi, Noor Dhaliwal, Sarah Hussain, Kathryn Dane, Harshvardhan Upreti, Evan M. Braunstein, Xuan Yuan, C. John Sperati, Alison R. Moliterno, Robert A. Brodsky

Blood Adv (2021) 5 (5): 1504–1512.

https://doi.org/10.1182/bloodadvances.2020003175

Published: 2021

Journal Articles

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

Jeremy D. Rubinstein, Xiang Zhu, Carolyn Lutzko, Tom Leemhuis, Jose A. Cancelas, Sonata Jodele, Catherine M. Bollard, Patrick J. Hanley, Stella M. Davies, Michael S. Grimley, Adam S. Nelson

Blood Adv (2020) 4 (14): 3252–3257.

https://doi.org/10.1182/bloodadvances.2020002252

Published: 2020

Journal Articles

Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes

Kimberly Lin, Lingjun Zhang, Michael Kong, Maojing Yang, Yinghua Chen, Earl Poptic, Melanie Hoffner, Jijun Xu, Connie Tam, Feng Lin

Blood Adv (2020) 4 (9): 2049–2057.

https://doi.org/10.1182/bloodadvances.2020001690

Published: 2020

Includes: Supplemental data

Journal Articles

Interferon-complement loop in transplant-associated thrombotic microangiopathy

Sonata Jodele, Mario Medvedovic, Nathan Luebbering, Jenny Chen, Christopher E. Dandoy, Benjamin L. Laskin, Stella M. Davies

Blood Adv (2020) 4 (6): 1166–1177.

https://doi.org/10.1182/bloodadvances.2020001515

Published: 2020

Includes: Supplemental data

Journal Articles

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program

Georg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, Nina Buchtele, Christian Sillaber, Michael Fillitz, Thomas M. Schenk, Shirley D’Sa, Ronwyn Cartwright, James C. Gilbert, Bernd Jilma, Ulrich Jaeger

Blood Adv (2020) 4 (6): 997–1005.

https://doi.org/10.1182/bloodadvances.2019001321

Published: 2020

Includes: Supplemental data

Journal Articles

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition

Sarah A. Lau-Braunhut, Hannah Stone, Griffin Collins, Sigbjørn Berentsen, Benjamin S. Braun, Matt S. Zinter

Blood Adv (2019) 3 (22): 3575–3578.

https://doi.org/10.1182/bloodadvances.2019000897

Published: 2019

Journal Articles

Heterogeneity in neutrophil responses to immune complexes

Madelaine Duarte, Maragatha Kuchibhatla, Sanjay Khandelwal, Gowthami M. Arepally, Grace M. Lee

Blood Adv (2019) 3 (19): 2778–2789.

https://doi.org/10.1182/bloodadvances.2019000235

Published: 2019

Includes: Supplemental data

Journal Articles

Absence of complement component 3 does not prevent classical pathway–mediated hemolysis

Lingjun Zhang, Yang Dai, Ping Huang, Thomas L. Saunders, David A. Fox, Jijun Xu, Feng Lin

Blood Adv (2019) 3 (12): 1808–1814.

https://doi.org/10.1182/bloodadvances.2019031591

Published: 2019

Journal Articles

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera

Richard B. Pouw, Mieke C. Brouwer, Marlon de Gast, Anna E. van Beek, Lambertus P. van den Heuvel, Christoph Q. Schmidt, Arie van der Ende, Pilar Sánchez-Corral, Taco W. Kuijpers, Diana Wouters

Blood Adv (2019) 3 (4): 621–632.

https://doi.org/10.1182/bloodadvances.2018025692

Published: 2019

Includes: Supplemental data

Journal Articles

Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD

Blood Adv (2018) 2 (20): 2619–2628.

https://doi.org/10.1182/bloodadvances.2018020321

Published: 2018

Includes: Supplemental data

Journal Articles

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Alexander Röth, Martin Bommer, Andreas Hüttmann, Dörte Herich-Terhürne, Nils Kuklik, Jan Rekowski, Veronika Lenz, Hubert Schrezenmeier, Ulrich Dührsen

Blood Adv (2018) 2 (19): 2543–2549.

https://doi.org/10.1182/bloodadvances.2018024190

Published: 2018

Journal Articles

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Alexander Röth, Scott T. Rottinghaus, Anita Hill, Eric S. Bachman, Jin Seok Kim, Hubert Schrezenmeier, Louis Terriou, Álvaro Urbano-Ispizua, Richard A. Wells, Jun Ho Jang, Austin G. Kulasekararaj, Jeff Szer, Rasha Aguzzi, Andrew I. Damokosh, Lori Shafner, Jong Wook Lee

Blood Adv (2018) 2 (17): 2176–2185.

https://doi.org/10.1182/bloodadvances.2018020644

Published: 2018

Includes: Supplemental data

Journal Articles

Complement-mediated thrombotic microangiopathy associated with lupus nephritis

Mi Hee Park, Nicholas Caselman, Scott Ulmer, Ilene Ceil Weitz

Blood Adv (2018) 2 (16): 2090–2094.

https://doi.org/10.1182/bloodadvances.2018019596

Published: 2018

Journal Articles

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

Nadine Müller-Calleja, Svenja Ritter, Anne Hollerbach, Tanja Falter, Karl J. Lackner, Wolfram Ruf

Blood Adv (2018) 2 (9): 979–986.

https://doi.org/10.1182/bloodadvances.2018017095

Published: 2018

Journal Articles

Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions

Priyanka Pandey, Waseem Q. Anani, Jerome L. Gottschall, Gregory A. Denomme

Blood Adv (2017) 1 (23): 1977–1982.

https://doi.org/10.1182/bloodadvances.2017008805

Published: 2017

Journal Articles

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b

Hua Zhou, Henrik Olsen, Edward So, Emmanuel Mérigeon, Denis Rybin, Jane Owens, Gregory LaRosa, David S. Block, Scott E. Strome, Xiaoyu Zhang

Blood Adv (2017) 1 (8): 504–515.

https://doi.org/10.1182/bloodadvances.2016001917

Published: 2017

Includes: Supplemental data

Journal Articles

Welcome to Blood Advances

Robert S. Negrin

Blood Adv (2016) 1 (1): 1.

https://doi.org/10.1182/bloodadvances.2016001677

Published: 2016

Journal Articles

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia

Douglas B. Cines, Serge V. Yarovoi, Sergei V. Zaitsev, Tatiana Lebedeva, Lubica Rauova, Mortimer Poncz, Gowthami M. Arepally, Sanjay Khandelwal, Victoria Stepanova, Ann H. Rux, Adam Cuker, Cecilia Guo, Linnette Mae Ocariza, Richard J. Travers, Stephanie A. Smith, Hugh Kim, James H. Morrissey, Edward M. Conway

Blood Adv (2016) 1 (1): 62–74.

https://doi.org/10.1182/bloodadvances.2016000877

Published: 2016

Includes: Supplemental data

NARROW

Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes

Interferon-complement loop in transplant-associated thrombotic microangiopathy

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition

Heterogeneity in neutrophil responses to immune complexes

Absence of complement component 3 does not prevent classical pathway–mediated hemolysis

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera

Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Complement-mediated thrombotic microangiopathy associated with lupus nephritis

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b

Welcome to Blood Advances

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only